Klickpfad

Rivaroxaban data at the ACC Annual Scientific Session

April 2 - 5, 2011
New Orleans, USA

Findings from the Phase III MAGELLAN study of Rivaroxaban were presented during at the Annual Scientific Session of the American College of Cardiology (ACC) in New Orleans, USA, on April 5, 2011, 3:00 p.m. - 3:12 p.m. CEST. On this occasion we held a conference call for investors and analysts.

Investor News Tuesday April 05, 2011

Not intended for U.S. Media - Prevention of VTE in hospitalized, acutely ill patients:

In the Prevention of VTE in Acutely ill Patients, Rivaroxaban Compares Favorably with Enoxaparin but Does Not Show a Consistent Net Clinical Benefit

MAGELLAN study meets primary efficacy endpoints of demonstrating non-inferiority in short-term use and superiority in long-term use / Primary analysis shows no consistent positive benefit-risk balance across heterogeneous patient population studied

Tuesday, April 5, 2011 at approx. 4:00 p.m. CEST (2:00 p.m. GMT): Investor Conference Call on Rivaroxaban

with
Dr. Kemal Malik, Head of Global Development at Bayer HealthCare Pharmaceuticals
Dr. Frank Misselwitz, Head Therapeutic Area Cardiovascular and Coagulation, Global Clinical Development
Dr. Alexander Rosar, Head of Investor Relations

Audio recording (MP3 format)